INGELHEIM, GERMANY, April 13, 2026

Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in dairy cows, marking a significant advancement in animal health and livestock disease management. The vaccine is engineered to reduce the incidence and severity of clinical mastitis, one of the most economically impactful diseases in dairy farming. With availability beginning across several European Union markets, LENZELTA® represents a key innovation in preventive veterinary medicine, supporting improved herd health, productivity, and farm sustainability.

Innovative Vaccine Targets Key Mastitis Pathogens

LENZELTA® specifically targets two major mastitis-causing pathogens, Staphylococcus aureus and Escherichia coli, which are responsible for a significant proportion of infections in dairy cattle. By focusing on these pathogens, the vaccine delivers early onset immunity and long-lasting protection, covering the critical period when cows are most vulnerable, particularly around calving. Administered in two doses during the dry-off period, the vaccine is designed to integrate seamlessly into existing herd health management practices. Its oil-free adjuvant formulation and flexible dosing options further enhance usability for veterinarians and farmers, making it a practical and effective preventive solution.

Enhancing Dairy Productivity and Animal Welfare

Mastitis is a widespread and costly disease that affects milk production, quality, and overall animal welfare. It is associated with significant economic losses due to reduced yield, treatment costs, and herd management challenges. LENZELTA® addresses these issues by enabling a proactive, prevention-focused approach, helping farmers maintain healthier herds and more stable milk production. The vaccine’s ability to reduce infection rates and severity supports improved animal well-being and operational efficiency, aligning with industry trends toward sustainable and responsible livestock management.

Advertisement

cGxPJobs Banner

Supporting Preventive Veterinary Care Strategies

The launch of LENZELTA® reinforces the growing emphasis on preventive healthcare in veterinary medicine, where early intervention plays a crucial role in minimizing disease burden and improving outcomes. By providing extended protection of up to six months, the vaccine ensures coverage during the most critical phases of the lactation cycle. This approach not only reduces reliance on therapeutic treatments but also contributes to better antimicrobial stewardship, an increasingly important consideration in global animal health. The innovation highlights Boehringer Ingelheim’s commitment to advancing science-driven solutions that benefit both animals and agricultural systems.

Driving Innovation in Animal Health and Agriculture

As a global leader in animal health, Boehringer Ingelheim continues to invest in research and development of vaccines and biologics that address key challenges in livestock management. The introduction of LENZELTA® expands the company’s mastitis prevention portfolio, offering veterinarians and farmers a new tool to combat a persistent industry issue. The development reflects broader trends in bio-pharmaceutical innovation within veterinary medicine, where targeted vaccines are playing an increasingly important role in improving productivity, sustainability, and food security.

The launch of LENZELTA® marks a significant step forward in mastitis prevention and veterinary vaccine innovation, providing a practical and effective solution for dairy farmers worldwide. With its targeted mechanism, ease of administration, and long-lasting protection, the vaccine is poised to improve herd health, economic outcomes, and sustainable farming practices. As the global demand for efficient and responsible agricultural systems continues to grow, innovations such as LENZELTA® highlight the critical role of veterinary bio-pharmaceuticals in supporting the future of livestock health and productivity

Source: Boehringer Ingelheim press release